腹膜转移癌内科治疗新进展  

Progress on chemotherapy for peritoneal carcinomatosis

作　　者：黄莹莹[1] 赵赟博[1] Yingying Huang;Yunbo Zhao(Department of Oncology,Beijing Hospital,National Center of Gerontology,Beijing 100730,China)

机构地区：[1]北京医院肿瘤内科,国家老年医学中心,北京市100730

出　　处：《中国肿瘤临床》2020年第3期123-127,共5页Chinese Journal of Clinical Oncology

摘　　要：腹膜转移癌因发现较晚且预后差,目前正成为研究热点。随着细胞减灭术及腹腔热灌注治疗的推广,部分经选择的患者获益。针对不同肿瘤的不同时期,大量的临床研究显示,用药选择、用药时机、用药方法方面均取得进展,尤其是加压腹腔内气溶胶化疗的使用减轻了治疗相关不良反应,并提高了疗效。本文就近年来腹膜转移癌的内科治疗进展进行阐述。Peritoneal carcinomatosis is obtaining extensive attention because of its late detection and poor prognosis.Lately,cytoreductive surgery(CRS)and hyperthermic intraperitoneal chemotherapy(HIPEC)are widely used for the treatment of this condition and could be effective in some carefully selected patients.Different chemotherapies are combined with CRS or HIPEC,and different drug administration routes are used,such as intraperitoneal or pressurized intraperitoneal aerosol chemotherapy.Furthermore,the results of many clinical trials differed among patients with different types of cancer.Herein,we reviewed recent studies in patients with gastric,colon,and ovarian cancer to evaluate the progress of chemotherapy for peritoneal carcinomatosis.

关 键 词：腹膜转移癌 腹腔化疗 热灌注化疗 加压腹腔内气溶胶化疗 细胞减灭术 

分 类 号：R735.5[医药卫生—肿瘤]